Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress

About this update from Biovica International Ab Class B

[{"type":"text","content":"UPPSALA, SE / ACCESS Newswire / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces financial goals for the upcoming two fiscal years. The targets reflect the company's recent commercial momentum and its long-term commitment to transparency and value creation for patients, healthcare providers, and shareholders.","length":411,"tagName":"p"},{"type":"text","content":"The recently communicated partner agreement with Tempus AI in the U.S. and the agreement with a leading healthcare provider, which was communicated in December 2024, are expected to generate significant revenues for Biovica. Along with more than 15 active collaborations with pharmaceutical companies representing a total project value of approximately 25 MSEK and the 18 active partnership agreements covering key European markets, the company has established a strong foundation for growth. On this basis, Biovica is now in a position to provide clear financial guidance.","length":573,"tagName":"p"},{"type":"text","content":"Biovica's financial targets:","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FY 2024/25 (ending April 30, 2025): Net sales of SEK 8.5 million","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"FY 2025/26: Net sales of SEK 50 million","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"FY 2026/27: Net sales of SEK 150 million","length":40,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":143,"olType":false},{"type":"text","content":"With expected operating expenses at the current level of approximately 90 MSEK per year, Biovica anticipates becoming cash-flow positive during the third quarter of FY 2026/27.","length":176,"tagName":"p"},{"type":"text","content":"The expected distribution of revenues during FY25/26 and FY 26/27 are:","length":70,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"65% from the U.S. market, driven by reimbursement and volume growth through strategic partnerships","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"30% from pharma services, based on ongoing and future biomarker collaborations","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"5% from European partners, through distributor and lab agreements...

More updates from Biovica International Ab Class B